November 2022 - Page 4 of 9

TuesdayNov 22, 2022 10:30 am

FuelPositive Corp. (TSX.V: NHHH) (OTCQB: NHHHF) Helping with the Switch to Cleaner Ammonia Generation in Light of the world’s 2050 Net Zero Goal

Ammonia is a highly efficient carrier of both hydrogen and nitrogen, with nitrogen being a critical component to fertilizers and world food production, but traditional ammonia production results in large greenhouse gas emissions FuelPositive’s carbon-free “green ammonia” production technology represents an environmentally superior way of producing ammonia The company’s confidence in its product has seen it go the extra mile to develop on-farm containerized, green ammonia production systems, that can be leveraged on a smaller scale to create green ammonia for agricultural fertilizers on-site FuelPositive (TSX.V: NHHH) (OTCQB: NHHHF), a company focused on licensing, partnership, and acquisition opportunities related to…

TuesdayNov 22, 2022 9:45 am

BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Director of Communications and Investor Relations Presents at LD Micro Main Event

BiondVax summarizes collaboration with the prestigious Max Planck Institute for Multidisciplinary Sciences and the University Medical Center Göttingen to discover and develop nanosized antibody (NanoAb) therapies that address underserved and growing markets, including COVID-19, psoriasis, asthma, psoriatic arthritis and wet macular degeneration. The global COVID-19 therapy market was valued at $16.8 billion in 2021 and is expected to grow at a CAGR of 20% during the forecast period, resulting in a value of $35.42 billion by 2025 The psoriasis market is experiencing a higher-than-expected demand across all regions due to the increasing geriatric population and the growing prevalence of plaque…

TuesdayNov 22, 2022 9:00 am

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Announces First European Dosing in Potentially Pivotal GBM Trial

The National Brain Tumor Society anticipates that more than 13,000 Americans will receive a GBM diagnosis during 2022, accounting for 49.1% of all primary malignant brain tumors CNS announced the first patient in Europe has been enrolled and dosed in the global trial to evaluate Berubicin for the treatment of GBM Berubicin is a novel anthracycline and the first to appear to cross the blood-brain barrier The global GBM treatment market is expected to reach a value of $4.2 billion by 2028, driven by the increased approval granted by the FDA for novel GBM treatment therapies CNS Pharmaceuticals (NASDAQ: CNSP),…

MondayNov 21, 2022 2:15 pm

RHK 2022 Disruptive Growth Conference to Encourage Budding Entrepreneurs with Growth Potential

The RHK Capital 2022 Disruptive Growth Conference, being held at the offices of Reed Smith in New York City, invites investors, capitalists, life science companies, growth companies and budding enterprises, for an interactive session of learning, networking, exchange of ideas, and business collaborations, spread over two days. The RHK Capital 2022 Disruptive Growth Conference offers a robust forum and an exclusive opportunity to discover disruptive growth companies. Up to 30 senior management teams from highly reputed companies will pitch their businesses to over 200 institutional investors, accredited investors, family offices, Wall Street analysts, financial advisors, broker-dealer wealth managers and RHK Capital…

MondayNov 21, 2022 1:30 pm

Vision Energy Corp. (VIHDD) Accelerates Efforts for Development of Pioneering Green Energy Terminal in North Sea Port of Vlissingen, the Netherlands

Vision Energy is in advanced stages of planning for construction and delivery of Northwestern Europe’s first import, storage and handling terminal designed exclusively for hydrogen carriers, renewable energy products and low-carbon fuels Vision Energy, through its wholly owned subsidiary Evolution Terminals BV, just announced partnership with Linde Engineering, a leading global industrial gases and engineering company, to deliver preliminary Front-End Engineering and Design (“FEED”) services to the project Green Energy Terminal Project will accelerate and advance the energy transition and facilitate Northwestern Europe’s ambition to achieve Net Zero through carbon-abatement and adoption of hydrogen as a core feedstock and fuel…

MondayNov 21, 2022 12:45 pm

Hillcrest Energy Technologies Ltd. (CSE: HEAT) (OTCQB: HLRTF) Helps Power Global EV Adoption through Innovation

Worldwide initiatives to slash carbon emissions, recently bolstered by the Inflation Reduction Act in the United States, are underpinned by EV uptake, which needs innovation to scale and reach critical mass Hillcrest Energy Technologies has developed a cutting-edge 250-kilowatt, 800-volt Silicon Carbide (“SiC”) EV inverter that has captured the attention of leading firms Hillcrest has recently inked new partnerships, including one with a global Tier 1 automotive supplier, for the purpose of commercializing new inverters for electric mobility applications With 1.4 billion vehicles in use today and around 1 percent of them powered by electricity, the move to decarbonize the…

MondayNov 21, 2022 12:00 pm

HeartBeam Inc. (NASDAQ: BEAT) Awarded Top Honors for Game-Changing Cardiovascular Tech Platform

BEAT named winner of the 2022 Cardiovascular Innovations (“CVI”) Innovation Summit and Shark Tank Competition Company’s presentation included an overview of its HeartBeam AIMI™ platform, which aids in more precise heart attack diagnosis HeartBeam is building an intellectual-property portfolio focused on enabling 12-lead electrocardiogram (“ECG”) diagnostics outside of a medical setting HeartBeam (NASDAQ: BEAT), a cardiac technology company that has developed the first and only 3D-vector ECG platform for heart attack detection anytime, anywhere, has been named winner of the annual Cardiovascular Innovations (“CVI”) 2022 Innovation Summit and Shark Tank Competition (https://nnw.fm/usMK4). The annual conference focuses on innovative health solutions…

MondayNov 21, 2022 11:15 am

Cepton, Inc. (NASDAQ: CPTN) to Solidify Its Financial Position With $100 Million Investment from Koito; Forges Ahead Toward Mass-Market Deployment of Its Lidar Technology

Cepton signed binding agreement with established automotive lighting tier 1 supplier Koito for investment of $100 million to bolster its next stage of growth Agreement penned on October 27, 2022, marks the third investment from this long-term automotive Tier 1 partner and existing shareholder since 2020 Lidar market expected to grow rapidly to reach $59 billion by 2030; Cepton appears to continue leading as a prominent figure, as it works toward commercialization and mass market deployment of its lidar sensors Following a previously reported letter of intent from Koito Manufacturing Co., Ltd. (TSE:7276), Cepton (NASDAQ: CPTN) has announced that it…

MondayNov 21, 2022 10:30 am

Odyssey Health, Inc. (ODYY) Expands Executive Team of New Subsidiary in Strategic Move to Strengthen Marketing of Concussion, Neurological Therapies

Brain injuries affect all aspects of society, from recreational youth athletics to military trauma interventions Despite the commonality of brain concussion injuries — more than 5 million a year in the United States alone — no FDA-approved therapy exists Medical technology innovator Odyssey Health Inc. is working toward a commercialized product treatment solution to the unmet need of concussion injuries Odyssey’s product for treating brain concussion has recently completed a series of human and animal safety trials and is now being prepped for Phase II/III trials focused on proving efficacy The product administers neurosteroids across the blood-brain barrier to stop…

MondayNov 21, 2022 9:45 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Kicks Off First-Ever Study on DehydraTECH-CBD for the Potential Treatment of Diabetes

In November 2021, Lexaria laid out its plans for several new and ongoing R&D programs, among them hormone replacement, dementia, rheumatoid disease, and diabetes The company has since begun its DIAB-A22-1 study program on the effectiveness of the patented DehydraTECH(TM)-processed CBD for the potential therapeutic utility against diabetes Lexaria is optimistic that the study will yield some notable results, particularly with DehydraTECH-CBD having met primary safety and efficacy objectives from its HYPER-H21-4 clinical study on the potential treatment of hypertension So far, CBD has shown some ability to reduce the incidence of diabetes in mice, and Lexaria looks to build…

Financial news and publishing for public and private companies

Contact us: 512.354.7000

Month: November 2022